- Conditions
- Advanced Solid Malignancies
- Interventions
- AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391, Trastuzumab Deruxtecan (T-DXd), Datopotamab Deruxtecan (Dato-DXd)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 695 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 11
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 697–720
of 720
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hematological Malignancy, Lymphoma
- Interventions
- SG2501
- Drug
- Lead sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Hackensack, New Jersey • Hawthorne, New York + 5 more
- Conditions
- Hypertension, Cardiovascular Diseases
- Interventions
- Vinyasa Yoga
- Behavioral
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Cancer of the Prostate, Neoplasms, Prostate, Prostate Cancer, Prostatic Cancer, Neoplasms, Prostatic, Prostate Neoplasms, Castration-resistant
- Interventions
- ASN001: Escalating dose Part A
- Drug
- Lead sponsor
- Asana BioSciences
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Detroit, Michigan • Cleveland, Ohio + 3 more
- Conditions
- Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Liver Neoplasms, Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Interventions
- PF-08634404, Ipilimumab
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 46
- States / cities
- Irvine, California • Los Angeles, California • Orange, California + 21 more
- Conditions
- Inoperable Solid Tumors or Lymphomas
- Interventions
- AvidinOX, 177Lu-ST2210
- Drug
- Lead sponsor
- Alfasigma S.p.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Alzheimer's Disease and Related Dementias
- Interventions
- EDITH-HC
- Behavioral
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 19 Years to 90 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Metastatic Prostate Cancer
- Interventions
- AZD5305, Enzalutamide, Abiraterone Acetate, Darolutamide, Apalutamide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Male only
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 6
- States / cities
- Detroit, Michigan • Syracuse, New York • Myrtle Beach, South Carolina + 1 more
- Conditions
- Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30+ Anaplastic Large Cell Lymphoma, CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma, CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma, Leukemia, Lymphoma
- Interventions
- anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC), GM-CSF
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Selected Types of Solid Tumor
- Interventions
- EVM14, Pembrolizumab
- Biological · Combination Product
- Lead sponsor
- Everest Medicines (Beijing) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 3
- States / cities
- New York, New York • Houston, Texas • Fairfax, Virginia
- Conditions
- Ulcerative Colitis
- Interventions
- RO7049665, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Lymphoma
- Interventions
- HMPL-689
- Drug
- Lead sponsor
- Hutchmed
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 10
- States / cities
- Anaheim, California • Oxnard, California • Atlanta, Georgia + 6 more
- Conditions
- Gram-Positive Bacterial Infections, Gram-Positive Bacteraemia, Substance Use Disorders, Intravenous Substance Abuse
- Interventions
- Dalbavancin
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Primary Familial Dilated Cardiomyopathy
- Interventions
- danicamtiv
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 12
- States / cities
- La Jolla, California • Washington D.C., District of Columbia • Tampa, Florida + 9 more
- Conditions
- Malaria, Plasmodium Falciparum Malaria
- Interventions
- Falciparum Malaria Protein 11 with AS02A adjuvant
- Biological
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
- Interventions
- TRX319, Bendamustine
- Biological · Drug
- Lead sponsor
- Tr1X, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 8
- States / cities
- La Jolla, California • Kansas City, Kansas • Rochester, Minnesota + 5 more
- Conditions
- Sarcoma, Oral Mucositis
- Interventions
- Caphosol, Baking Soda
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Sclerosis
- Interventions
- Placebo, BMS 188667 (Abatacept)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 10
- States / cities
- New Haven, Connecticut • Louisville, Kentucky • Worcester, Massachusetts + 7 more
- Conditions
- Solid Tumors, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Interventions
- PLX51107
- Drug
- Lead sponsor
- Plexxikon
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 5
- States / cities
- New York, New York • Columbus, Ohio • Philadelphia, Pennsylvania + 2 more
- Conditions
- Recurrent Glioblastoma, IDH-Wildtype, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Astrocytoma, Grade IV
- Interventions
- Allogeneic Adipose-derived Mesenchymal Stem Cells, Biospecimen Collection, Craniotomy, Magnetic Resonance Imaging, Ommaya Reservoir Tap
- Biological · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Advanced Solid Tumors
- Interventions
- intravenous (IV) infusion
- Drug
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 11
- States / cities
- Denver, Colorado • New Haven, Connecticut • Lake Mary, Florida + 8 more
- Conditions
- Muscle Spasticity
- Interventions
- tolperisone HCl (AV650), Placebo
- Drug
- Lead sponsor
- Avigen
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 9
- States / cities
- Pasadena, California • Miami, Florida • Atlanta, Georgia + 5 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Atezolizumab
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma, Lymphoma, Primary Central Nervous System Lymphoma
- Interventions
- CC-122
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 17
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 13 more